FAP-targeted radiopharmaceuticals represent a breakthrough in cancer imaging and a viable option for therapeutic applications. OncoFAP is an ultra-high-affinity ligand of FAP with a dissociation constant of 680 pM. OncoFAP has been recently discovered and clinically validated for PET imaging procedures in patients with solid malignancies. While more and more clinical validation is becoming available, the need for scalable and robust procedures for the preparation of this new class of radiopharmaceuticals continues to increase. In this article, we present the development of automated radiolabeling procedures for the preparation of OncoFAP-based radiopharmaceuticals for cancer imaging and therapy. A new series of [68Ga]Ga-OncoFAP, [177Lu]Lu-O...
Simple Summary FAP-targeted radiotracers, recently introduced in cancer treatment, accumulate in Ca...
Radiolabeled tracers targeting the prostate-specific membrane antigen (PSMA) have become important r...
Primary aldosteronism (PA) is the leading secondary cause of hypertension. Determining whether one (...
FAP-targeted radiopharmaceuticals represent a breakthrough in cancer imaging and a viable option for...
Purpose The fibroblast activation protein (FAP) is an emerging target for molecular imaging and ther...
Fibroblast activation protein (FAP), a type II integral membrane serine protease, is a promising tar...
© 2014 Dr. Mohammad Baqir HaskaliPositron Emission Tomography (PET) is a molecular imaging technique...
Fibroblast activation protein (FAP) is expressed in the microenvironment of most human epithelial tu...
The neurotracer 6-[18F] FDOPA has been, for many years, a powerful tool in PET imaging of neuropsych...
The biological properties of receptor-targeted peptides have made them popular diagnostic imaging an...
The fluorine-18 radiolabelled octreotide derivative [18F]FET-βAG-TOCA targeting somatostatin recepto...
Background [F-18]MC225 is a radiotracer for imaging P-glycoprotein (P-gp) function at the blood-brai...
Background: Prostate-specific membrane antigen (PSMA) is frequently overexpressed a...
Positron emission tomography (PET) is a rapidly expanding clinical modality worldwide thanks to the ...
Background: Noninvasive molecular imaging using peptides and biomolecules labelled with positron emi...
Simple Summary FAP-targeted radiotracers, recently introduced in cancer treatment, accumulate in Ca...
Radiolabeled tracers targeting the prostate-specific membrane antigen (PSMA) have become important r...
Primary aldosteronism (PA) is the leading secondary cause of hypertension. Determining whether one (...
FAP-targeted radiopharmaceuticals represent a breakthrough in cancer imaging and a viable option for...
Purpose The fibroblast activation protein (FAP) is an emerging target for molecular imaging and ther...
Fibroblast activation protein (FAP), a type II integral membrane serine protease, is a promising tar...
© 2014 Dr. Mohammad Baqir HaskaliPositron Emission Tomography (PET) is a molecular imaging technique...
Fibroblast activation protein (FAP) is expressed in the microenvironment of most human epithelial tu...
The neurotracer 6-[18F] FDOPA has been, for many years, a powerful tool in PET imaging of neuropsych...
The biological properties of receptor-targeted peptides have made them popular diagnostic imaging an...
The fluorine-18 radiolabelled octreotide derivative [18F]FET-βAG-TOCA targeting somatostatin recepto...
Background [F-18]MC225 is a radiotracer for imaging P-glycoprotein (P-gp) function at the blood-brai...
Background: Prostate-specific membrane antigen (PSMA) is frequently overexpressed a...
Positron emission tomography (PET) is a rapidly expanding clinical modality worldwide thanks to the ...
Background: Noninvasive molecular imaging using peptides and biomolecules labelled with positron emi...
Simple Summary FAP-targeted radiotracers, recently introduced in cancer treatment, accumulate in Ca...
Radiolabeled tracers targeting the prostate-specific membrane antigen (PSMA) have become important r...
Primary aldosteronism (PA) is the leading secondary cause of hypertension. Determining whether one (...